110.42 0.00 (0.00%)
After hours: 4:19PM EST
|Bid||97.49 x 200|
|Ask||113.00 x 100|
|Day's Range||109.98 - 112.60|
|52 Week Range||80.69 - 126.89|
|Beta (3Y Monthly)||1.81|
|PE Ratio (TTM)||42.68|
|Earnings Date||Feb 25, 2019 - Mar 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||134.20|
Masimo (MASI) Founder and CEO Joe Kiani was honored last night at the 2018 IPO Education Foundation Awards Dinner with the first ever IP Champion Award. The Intellectual Property Owners Education Foundation, a non-profit organization devoted to educating the public on the importance of IP to society, has been awarding an Inventor of the Year for 45 years and Distinguished IP Professional for 10 years. Retired Chief Judge Paul Michel, formerly U.S. Circuit Judge of the U.S. Court of Appeals for the Federal Circuit and Chief Judge of that court, commented, “Serial inventor Joe Kiani built a major patient health improving company, starting from scratch at age 23, obtaining VC funding based on his patent applications when patents were strong.
For his "Executive Decision" segment of Mad Money Tuesday night, Jim Cramer sat down with Joe Kiani, CEO of Masimo Corp. Kiani said that opioids remain a leading cause of death in our country and Masimo's new patient monitoring equipment aims to eliminate the "dead in bed" phenomenon where patients fall asleep and never wake up. In this daily bar chart of MASI, below, we can see an interesting set up with the charts and indicators.
Concerns over rising interest rates and expected further rate increases have hit several stocks hard since the end of the third quarter. NASDAQ and Russell 2000 indices are already in correction territory. More importantly, Russell 2000 ETF (IWM) underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points in the first half of […]
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). We'll look at Masimo Corporation's (NASDAQ:MASI) P/E ratio and reflect on Read More...
Masimo (MASI) gains from solid prospects in the SET Pulse Oximeter platform. However, cutthroat competition in the MedTech space is likely to hurt the stock.
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, Nov. 29, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Medtronic's (MDT) resolve to take over the Israel-based robotic surgical guidance systems company, Mazor Robotics, adheres to its goal to grow in the sphere of robotics spine surgery.
Hill Rom (HRC) sets sights on product innovation. In patient support systems, the company unveils Hill-Rom Envella Air Fluidized Therapy Bed.
Haemonetics (HAE) sees encouraging growth at the North America Plasma revenues on strong disposables along with growing software revenues.
Masimo announced today that a new consensus statement on postoperative anemia management was published in Anaesthesia by an international panel of clinicians specializing in patient blood management, which includes clear guidance on the use and benefits of noninvasive hemoglobin measurement.1 The statement, which discusses both spot-check and continuous measurement, references the Masimo Rad-67™ Pulse ...
Masimo Corporation (NASDAQ:MASI), which is in the medical equipment business, and is based in United States, saw a decent share price growth in the teens level on the NasdaqGS over Read More...
Masimo today announced that its management is scheduled to present at the Stifel 2018 Healthcare Conference at the Palace Hotel in New York on Wednesday, November 14, 2018 at 10:15 a.m.
Jim Cramer sits down with Masimo Corp. founder, Chairman and CEO Joe Kiani to discuss how his company is innovating to help stem the U.S. opioid epidemic.